23 results about "Diastolic function" patented technology

Quinazoline dione compounds are provided for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction. Diseases treated by the methods described herein include, but are not limited to, cardiomyopathy, hypertrophic cardiomyopathy (HCM), abnormal heart rhythms, aortic disease, Marfan syndrome, coronary artery disease, heart attack, heart failure, rheumatic heart disease, peripheral vascular disease, stroke, deep vein thrombosis, and pulmonary embolism.

The invention discloses an application of glycogen synthase kinase 3beta in preparation of antihypertensive drugs. The GSK3beta gene is inserted into a GV652 plasmid and is packaged into an adeno-associated virus, so that specific overexpression of the adeno-associated virus in vascular endothelial cells is realized, and the adeno-associated virus is used for preparing medicines for treating hypertension. It is found for the first time that overexpression of GSK3beta in endothelial cells can improve the endothelial dependent relaxation function and reduce blood pressure. Mechanism research shows that serine 9-site phosphorylation of GSK3beta can activate an AKT-eNOS signal channel and promote release of nitric oxide, so that the endothelial function is improved, and the antihypertensive effect is achieved. Furthermore, glycine can promote phosphorylation of the GSK3beta Ser9 site, and AKT-eNOS signal activation and NO generation are enhanced. The invention provides a novel anti-hypertension gene therapy strategy for regulating and controlling an endothelial function based on a GSK3beta gene.

Disclosed is a cardiac diastolic function assessment method applicable to the field of cardiac monitoring. The method comprises: acquiring vibration information of the thoracic cavity body surface of an object in a noninvasive manner; preprocessing the vibration information to generate hemodynamic-related information; determining a target wave group on the basis of the hemodynamic-related information; determining the highest peak on the target wave group, determining a rising edge amplitude before the highest peak as a first characteristic value, and determining, as a second characteristic value, an amplitude between the highest peak and the subsequent lowest valley; and generating an indicating parameter on the basis of the first characteristic value and the second characteristic value, and assessing a cardiac diastolic function of the object on the basis of the indicating parameter.

The invention discloses a millimeter wave radar heart failure diagnosis system based on a CNN and LSTM ordinal regression hybrid model, and the system comprises a radar signal processing module which is used for obtaining a radar signal and forming a slow time-distance complex matrix; the physical sign signal extraction module is used for obtaining a physical sign time sequence signal from the complex matrix; the heartbeat waveform separation module is used for generating a filtering interval according to the heart rate and extracting a heartbeat vibration waveform; the deep feature learning module is used for constructing a feature extraction network for the heartbeat vibration waveform and outputting continuous score prediction; and the ordinal regression diagnosis module is used for establishing a learnable threshold value based on continuous score prediction and generating an ejection function and diastolic function grading result. Accurate modeling of millimeter wave radar non-contact heart failure grading diagnosis is achieved, and heart function evaluation convenience and evaluation accuracy are improved.

The application belongs to the technical field of biological medicine, and particularly relates to application of a GCN2 kinase inhibitor in preparation of a drug for treating heart failure with preserved ejection fraction. 18 H 12 ClF2N5O3S, the inhibitor can inhibit the activity of GCN2 kinase, and exhibits significant therapeutic effect in a disease model: can obviously improve ventricular diastolic function (E / E' ratio is reduced), reduce the level of heart failure markers, reduce cardiomyocyte hypertrophy and interstitial fibrosis, inhibit the expression of oxidative stress level and inflammatory factors, reduce the accumulation of triglyceride and total cholesterol in myocardium and serum, and improve obesity-related insulin resistance and metabolic disorder. The application provides a novel targeted treatment strategy and candidate drug for heart failure with preserved ejection fraction.

A method (100) for classifying a patient's diastolic function, comprising: (i) receiving (120), from an ultrasound device (280), a plurality of 2D echocardiographic images of the patient's heart; (ii) analyzing (150), by a trained diastolic function prediction algorithm, the plurality of 2D echocardiographic images of the patient's heart to estimate left ventricular end-diastolic pressure (LVEDP); (iii) classifying (160) the patient's diastolic function as normal or abnormal based on the estimated LVEDP; and (iv) providing (170), to a user via a user interface, an indication of the patient's diastolic function as normal or abnormal.

Methods and materials for treating chronic cardiac disorders are provided herein. For example, methods and materials for using a dual guanylate cyclase A and B activator (e.g., a polypeptide having the sequence set forth in SEQ ID NO:1) to treat hypertrophic cardiomyopathy and other cardiac conditions, such as conditions associated with ventricular hypertrophy, atrial hypertrophy, ventricular remodeling, atrial remodeling, systolic and / or diastolic dysfunction, heart failure (e.g., heart failure with reduced ejection fraction, heart failure with mildly reduced ejection fraction, and heart failure with preserved ejection fraction), and other forms of chronic heart disease (e.g., Fabry disease, Noonan syndrome, Pompe disease, PRKAG2-related cardiomyopathy, Danon disease, Friedrich ataxia cardiomyopathy, amyloidosis, or desminopathy) are provided herein.

Providing quinazolindione compounds and their uses. [Solution] Quinazoline dione compounds are provided for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction. Diseases treated by the methods described herein include, but are not limited to, cardiomyopathy, hypertrophic cardiomyopathy (HCM), abnormal heart rhythms, aortic disease, Marfan syndrome, coronary artery disease, heart attack, heart failure, rheumatic heart disease, peripheral vascular disease, stroke, deep vein thrombosis, and pulmonary embolism.

A cardiac diastolic function assessment method, for use in the field of cardiac monitoring. The method comprises: noninvasively acquiring vibration information of the thoracic body surface of a subject; preprocessing the vibration information to generate hemodynamics-related information; determining a first parameter and a second parameter on the basis of the hemodynamics-related information; generating an indicating parameter on the basis of the first parameter and of the second parameter, and assessing the cardiac diastolic function of the subject on the basis of the indicating parameter.

The invention discloses an application of a composition of a CD36 inhibitor and a PDK4 inhibitor in preparation of a medicine for treating HFpEF, and the CD36 inhibitor and the PDK4 inhibitor are combined for use and are used for cooperatively regulating and controlling myocardial metabolism reprogramming so as to treat the HFpEF. Through combined application of the CD36 inhibitor and the PDK4 inhibitor, the effects of the combined scheme on a plurality of key indexes such as improvement of the heart diastolic function of an HFpEF mouse, improvement of exercise tolerance, reversal of cardiac hypertrophy, reduction of pulmonary congestion and myocardial fibrosis and the like are remarkably superior to those of any single-drug treatment group of SSO or DCA, and synergistic treatment is achieved.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a modified Zhenwu decoction traditional Chinese medicine compound and application thereof. The traditional Chinese medicine compound of the modified true Wu decoction is prepared from the following raw materials in parts by weight: 10 to 30 parts of radix aconiti lateralis praeparata slices, 6 to 18 parts of sun-dried ginseng, 10 to 30 parts of poria cocos, 8 to 24 parts of raw rhizoma atractylodis macrocephalae, 10 to 30 parts of radix paeoniae alba, 20 to 60 parts of pubescent holly root and 4 to 12 parts of rhodiola rosea. Clinical observation finds that the flavored Zhenwu decoction is an effective drug for resisting HFpEF, and can reverse cardiac hypertrophy of HFpEF mice, relieve pulmonary edema conditions, remarkably improve the diastolic function, improve HFpEF cardiac hypertrophy, improve cardiac diastolic dysfunction, improve myocardial injury and collagen deposition and improve myocardial cell mitochondrial injury.

Quinazoline dione compounds are provided for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction. Diseases treated by the methods described herein include, but are not limited to, cardiomyopathy, hypertrophic cardiomyopathy (HCM), abnormal heart rhythms, aortic disease, Marfan syndrome, coronary artery disease, heart attack, heart failure, rheumatic heart disease, peripheral vascular disease, stroke, deep vein thrombosis, and pulmonary embolism.

The application provides application of IL-17A as a target point in preparation of a drug for screening treatment or prevention of cardiac arrest. The application also provides application of IL-17A as a target point in preparation of a monoclonal antibody drug for screening treatment or prevention of cardiac arrest. The application also provides application of an anti-IL-17A monoclonal antibody in preparation of a drug for improving post-cardiac arrest syndrome. The application provides application of an anti-IL-17A monoclonal antibody in preparation of a drug for early intervention of cardiac arrest. The application also provides application of an anti-IL-17A monoclonal antibody in preparation of a drug for improving myocardial injury, cardiac dysfunction, brain injury or neurological dysfunction caused by cardiac arrest. The application also provides application of a reagent for detecting IL-17A level in serum in preparation of a kit for detecting a myocardial infarction combined with cardiac arrest patient. The application proves by experiments that IL-17 related pathways in heart and brain tissues are significantly activated after cardiac arrest, and IL-17A in serum is significantly increased, and early antagonism of IL-17A by using an IL-17A monoclonal antibody after resuscitation can improve myocardial injury, cardiac dysfunction (systolic and diastolic dysfunction), brain tissue injury or neurological dysfunction after cardiac arrest, and improve survival rate after cardiac arrest.

This invention discloses the application of apolipoprotein M in the preparation of a medicament for treating heart failure with preserved ejection fraction (HFpEF). The medicament comprises apolipoprotein M and a medically acceptable carrier or excipient. Animal experiments have shown that liver-specific overexpression of ApoM improves diastolic dysfunction, myocardial hypertrophy, and myocardial fibrosis in HFpEF mice, while liver-specific knockdown of ApoM exacerbates this pathological process. This provides a novel treatment strategy for HFpEF and also offers a theoretical basis for ApoM as a biomarker for HFpEF.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for improving diabetes mellitus complicated with ejection fraction retention type heart failure, a pharmaceutical preparation, a preparation method and application. The traditional Chinese medicine composition comprises the following raw materials in parts by weight: 5-15 parts of ginseng, 10-30 parts of astragalus membranaceus, 5-15 parts of coptis chinensis, 5-15 parts of polygonum cuspidatum, 10-30 parts of radix puerariae and 20-40 parts of caulis spatholobi. After the traditional Chinese medicine composition is used for treating mice, FBG and body weight of the mice are not obviously changed, but the insulin sensitivity can be increased, the high glucose state of cardiac metabolism can be improved, the diastolic dysfunction of DM-HFpEF mice can be relieved, meanwhile, the traditional Chinese medicine composition can relieve cardiac microvascular fibrosis by influencing the EndMT process, and the curative effect is good. The invention further illustrates that the traditional Chinese medicine composition mediates cell autophagy to intervene in'cell failure-EndMT 'to improve the potential action mechanism of cardiac fibrosis.

The disclosure provides methods, treatments and materials for enhancing the effect of an adenosine A2 receptor agonist in the treatment, mitigation or prophylaxis of a disease or condition characterized by inotropic and / or lusitropic dysfunction, and / or enhancing adenosine A2 receptor function in the treatment, mitigation or prophylaxis of a disease or condition characterized by impaired adenosine A2 receptor function, comprising administration of an effective amount of a PDE1 inhibitor to a patient in need thereof, for example a patient suffering from heart failure.

Provided are quinazolinone dione compounds for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction.

The invention discloses application of puerarin in preparation of a medicine for preventing and / or treating cardiovascular aging. The puerarin improves the NAD < + > level, activates SIRT3, improves the diastolic function and relieves myocardial fibrosis by targeting CD38 protein. The medicine can be prepared into tablets, capsules or injections. The invention discloses the action mechanism of puerarin for cardiovascular aging for the first time, and provides a new direction and a theoretical basis for the application of puerarin in the development of anti-aging drugs.

The invention relates to the technical field of biological medicines, in particular to application of an insulin-like growth factor 2 receptor IGF2R inhibitor in preparation of a medicine for preventing and / or treating fulminant myocarditis. The result of the embodiment of the invention shows that the IGF2R expression of the heart tissue is abnormally increased in the state of fulminating myocarditis, and is more obvious in myocardial cells. Expression and / or related biological functions of IGF2R are / is inhibited in a myocardial cell specific mode, the survival outcome of an animal model with fulminating myocarditis can be improved, the systolic and diastolic functions of the heart can be improved, myocardial damage markers are reduced, myocardial tissue inflammatory response is relieved, and the inflammatory factor level is reduced. The application disclosed by the invention is suitable for fulminating myocarditis types including but not limited to viral fulminating myocarditis, and a new intervention strategy and a potential drug target can be provided for the diseases.

The application discloses application of BCKDK gene as a target point in preparation of a medicine for preventing or treating obesity-related cardiomyopathy. The application firstly determines an important function of BCKDK in obesity-related cardiomyopathy, and overexpression of the BCKDK gene can protect the heart. The application also provides application of a nucleic acid molecule coding BCKDK, an expression vector or a delivery system containing the same, and application of BCKDK or the nucleic acid molecule coding BCKDK as a drug target. Preferably, the drug adopts an adeno-associated virus vector driven by a myocardium-specific promoter, carries a coding sequence of BCKDK or a functional variant, a truncated body or a functional fragment of BCKDK, and realizes myocardium-specific expression. Experiments prove that overexpression of BCKDK can significantly improve myocardial hypertrophy, fibrosis and diastolic dysfunction.

A system and method for prolonged organ preservation and real-time ex-vivo organ assessment. The organ perfusion and assessment system includes three components: A full cardiac output circuit, a resuscitation and low flow circuit, and an organ indexing stack to perform real-time hemodynamic ex-vivo organ assessment. A containment vessel maintains sterility and allows for complete echo-analysis. The slope of preload recruitable stroke work (PRSW) and other load-independent and load-dependent assays are used to stratify donor heart function. The best assessment of systolic function and therefore transplant suitability appears to be PRSW; the best systolic function is seen with full support of a donor heart. The best assessment of diastolic dysfunction appears to be Tau; the best diastolic function is also seen with full support of a donor organ. Load independent assessments appear to be highly repeatable and should identify currently discarded human donor hearts that are actually suitable for transplantation.